A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00535236 |
Recruitment Status :
Completed
First Posted : September 26, 2007
Results First Posted : April 16, 2019
Last Update Posted : May 20, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Herpes Zoster Herpes Zoster-related Complications | Biological: V212 Biological: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 341 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Prevention |
Official Title: | A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults |
Actual Study Start Date : | November 2, 2007 |
Actual Primary Completion Date : | January 25, 2010 |
Actual Study Completion Date : | January 26, 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Autologous HCT-V212
Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: V212
0.65 ml V212 in 4 dose regimen. Treatment period of 125 days |
Placebo Comparator: Autologous HCT-Placebo
Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: Placebo
0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days |
Experimental: Allogeneic HCT-V212
Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: V212
0.65 ml V212 in 4 dose regimen. Treatment period of 125 days |
Placebo Comparator: Allogeneic HCT-Placebo
Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: Placebo
0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days |
Experimental: STM-V212
Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: V212
0.65 ml V212 in 4 dose regimen. Treatment period of 125 days |
Placebo Comparator: STM-Placebo
Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: Placebo
0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days |
Experimental: HM-V212
Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: V212
0.65 ml V212 in 4 dose regimen. Treatment period of 125 days |
Placebo Comparator: HM-Placebo
Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: Placebo
0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days |
Experimental: HIV-V212
Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: V212
0.65 ml V212 in 4 dose regimen. Treatment period of 125 days |
Placebo Comparator: HIV-Placebo
Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
|
Biological: Placebo
0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days |
- Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) [ Time Frame: Baseline (Day 1 predose vaccination 1) and 28 days postdose 4 (~Day 118) ]Blood sample taken at predose (Day 1) and 28 days post vaccination 4 to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination
- Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by by VZV Interferon-gamma (IFN-g) Enzyme-linked Immunospot (ELISPOT) Assay [ Time Frame: Baseline (Day 1 predose vaccination 1) and 28 days postdose 4 (~Day 118) ]Blood sample taken at predose (Day 1) and 28 days post vaccination 4 to determine the geometric mean titre (GMT) of VZV antibodies via ELISPOT. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination
- Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE) [ Time Frame: up to 28 days post vaccination 4 (up to ~Day 118) ]An SAE was defined as an adverse event that resulted in death, was life threatening, resulted in persistent or significant disability or incapacity, resulted in or prolonged a hospitalization, is a congenital anomaly or birth defect, is a cancer, was an overdose, or was an important medical event based on appropriate medical judgment. The percentage of participants that experienced at least 1 SAE was summarized.
- Percentage of Participants With an Injection-site Adverse Event Prompted on the Vaccination Report Card (VRC) [ Time Frame: Up to Day 5 post any vaccination ]An adverse event (AE) was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with study drug. An AE could therefore have been any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the study drug or protocol-specified procedure was also an AE. The percentage of participants with an injection-site AE prompted on the VRC was summarized.
- Percentage of Participants With a Systemic Adverse Event Prompted on the VRC [ Time Frame: Up to 28 days post vaccination 4 (up to ~118 days) ]An adverse event (AE) was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with study drug. An AE could therefore have been any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the study drug or protocol-specified procedure was also an AE. The percentage of participants with a VRC-prompted systemic (non-injection site) AE was summarized.
- Percentage of Participants With Elevated Oral Temperature (≥101.0°F (≥38.3ºC) Prompted on the VRC [ Time Frame: Up to 28 days post any vaccination (up to ~118 days) ]Participants were instructed on the VRC to take and record their oral (or oral equivalent) temperature daily from the day of vaccination from the date of each vaccine dose through the day prior to the next dose, or for 28 days. Elevated temperature was defined as ≥101.0°F (≥38.3ºC). The percentage of participants that record an elevated temperature was summarized.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women > or = to 18 years of age who are scheduled to receive an autologous or allogeneic hematopoietic cell transplant within 60 days of enrollment
- HIV-infected participants with a baseline CD4 cell count < or = to 200 cells/mm^3
- Participants with hematologic malignancies; or participants who are receiving chemotherapy for breast, colorectal, lung, or ovarian malignancies
Exclusion Criteria:
- History of allergy to any vaccine component
- Prior history of HZ
- Prior history of receipt of any varicella or zoster vaccine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00535236
Study Director: | Medical Director | Merck Sharp & Dohme Corp. |
Responsible Party: | Merck Sharp & Dohme Corp. |
ClinicalTrials.gov Identifier: | NCT00535236 |
Other Study ID Numbers: |
V212-002 2007_608 ( Other Identifier: Merck ) V212-002 ( Other Identifier: Merck ) |
First Posted: | September 26, 2007 Key Record Dates |
Results First Posted: | April 16, 2019 |
Last Update Posted: | May 20, 2019 |
Last Verified: | May 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf |
URL: | http://engagezone.msd.com/ds_documentation.php |
Prevention of herpes zoster and HZ-related complications |
Herpes Zoster Chickenpox Varicella Zoster Virus Infection |
Herpesviridae Infections DNA Virus Infections Virus Diseases |